Articles By Jack Cush, MD
The RheumNow Week in Review – 2 June 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com.
Read Article
Chondroitin Effective in Knee OA. Or is it?
Reginster and colleagues have reported on the results of the CONCEPT trial showing that osteoarthritis (OA) patients treated 800 mg/day of pharmaceutical-grade chondroitin sulfate (CS) have less VAS pain scores and improved function over 6 months therapy. These results were superior to placebo and equivalent to celecoxib in reducing in symptomatic OA knee pain.
Read Article
Ohio Sues Five Pharma Companies Over Opioid Epidemic
Ohio is suing five major drug manufacturers, accusing them of misrepresenting the risks of prescription opioid painkillers that has resulted in the current opioid epidemic.
Read Article
New BSR 2017 Gout Guidelines
The British Society for Rheumatology/British Health Professionals in Rheumatology first published a guideline for the management of gout in 2007. They have just updated and published their new guideline, largely because of new therapies, an increasing incidence of gout, low penetrance of urate lowering therapies, and the inability to achieve a target serum uric acid level.
Read Article
Golimumab Fails in Polyarticular Juvenile Arthritis
Treatment options for children with active polyarticular juvenile idiopathic arthritis (polyJIA) have lagged behind that seen with adult rheumatoid arthritis.
Read Article
Biologics Before Triple DMARD is Not Cost Effective in Rheumatoid Arthritis
Stepping up to biologic therapy when methotrexate (MTX) monotherapy fails was not shown to be cost effective, compared to first trying triple therapy, in a rheumatoid arthritis (RA) study published in Annals of Internal Medicine.
Read Article
High Fiber Intake May Decrease Osteoarthritis Knee Pain
Dai, Felson and colleagues report in Annals of Rheumatic Disease that high dietary fiber lowers the risk of symptomatic osteoathritis (SxOA), but the radiographic benefits remain unclear. (Citation source http://buff.ly/2rHv9yd)
Read Article
The RheumNow Week in Review - 26 May 2017
Dr. Jack Cush Reviews highlights from the past week on RheumNow.com:
Read Article
Ixekizumab Effective in TNF Failure Psoriatic Arthritis - SPIRIT-P2 Trial
Ixekizumab (Taltz) is currently approved for use in plaque psoriasis and is being developed for use in psoriatic arthritis (PsA). New results show IXE to be highly effective at skin and joint outcomes in PsA patients who have failed a TNF inhibitor (TNFi).
Read Article
NLRP3 Activation in Still's Disease
Adult-onset Still disease (AOSD) is usually regarded as an autoinflammatory disease, largely because of its symptomatology and responsiveness to IL-1 inhibition.
Read Article
